Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics Inc (NQ: GLUE )

6.360 +0.290 (+4.78%)
Streaming Delayed Price Updated: 11:30 AM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,627
Open 6.060
Bid (Size) 6.330 (1)
Ask (Size) 6.390 (4)
Prev. Close 6.070
Today's Range 6.060 - 6.360
52wk Range 4.400 - 10.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-18.25%
-18.25%
1 Month
+4.61%
+4.61%
3 Month
-2.30%
-2.30%
6 Month
-5.07%
-5.07%
1 Year
-13.82%
-13.82%

More News

Read More
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Dow Surges 150 Points; Crude Oil Falls Sharply
Via Benzinga
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Albertsons Companies, Domino's Pizza And Other Big Gainers From Thursday
Via Benzinga
Monte Rosa Shares Rise As FDA Announced Clearance To MYC-Driven Cancer Study
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
53 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
56 Biggest Movers From Friday
Via Benzinga
66 Biggest Movers From Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.